About Diadexus
Diadexus is a company based in San Francisco (United States) founded in 1997 was acquired by Diazyme Laboratories in April 2016. Diadexus has raised $49.2 million across 3 funding rounds from investors including Burrill and Company, Diazyme Laboratories and Scale Venture Partners. Diadexus offers products and services including Serum Amyloid A Assay, Pancreatic Elastase Assay, DZ-Lite c270 Analyzer, OxPL Lipoprotein Assay, and Procalcitonin Assay. Diadexus operates in a competitive market with competitors including SD Biosensor, GEN inCode, SpectraWAVE, Realview Imaging and Lepu Medical Technology, among others.
- Headquarter San Francisco, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Diazyme Laboratories Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$49.2 M (USD)
in 3 rounds
-
Latest Funding Round
$4.5 M (USD), Debt – Conventional
Jun 08, 2010
-
Investors
Burrill and Company
& 5 more
-
Employee Count
Not available
-
Acquired by
Diazyme Laboratories
(Apr 01, 2016)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Diadexus
Diadexus offers a comprehensive portfolio of products and services, including Serum Amyloid A Assay, Pancreatic Elastase Assay, DZ-Lite c270 Analyzer, OxPL Lipoprotein Assay, and Procalcitonin Assay.
Immunoturbidimetric assay for detecting inflammatory markers
Test for pancreatic function in clinical samples
Fully-automated chemistry analyzer for lab testing
Chemiluminescent assay for cardiovascular markers
Quantitative test for sepsis and infection indicators
Funding Insights of Diadexus
Diadexus has successfully raised a total of $49.2M across 3 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $4.5 million completed in June 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Diadexus
Diadexus has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Burrill and Company, Diazyme Laboratories and Scale Venture Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage venture capital investments are focused on US companies.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on multiple sectors
|
Locked | Locked | Locked | |
|
Growth & late stage life sciences and tech focused venture capital firm funding companies in the US
|
Locked | Locked | Locked |
Investor details for Diadexus
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Diadexus
Investment portfolio details for Diadexus
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Diadexus
Detailed financials for Diadexus
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Diadexus Comparisons
Peer comparison for Diadexus
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Diadexus
Diadexus operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as SD Biosensor, GEN inCode, SpectraWAVE, Realview Imaging and Lepu Medical Technology, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Biosensors for point-of-care diagnostics are developed by SD Biosensor.
|
|
| Locked | Locked | Locked |
Genetic and clinical data are integrated for precision cardiac medicines.
|
|
| Locked | Locked | Locked |
Photonic imaging diagnostics for cardiovascular disease treatment are provided.
|
|
| Locked | Locked | Locked |
3D holographic display solutions for medical imaging are provided.
|
|
| Locked | Locked | Locked |
Interventional cardiology devices are developed and marketed globally.
|
Detailed competitors of Diadexus
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Diadexus
Complete news archive for Diadexus
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Diadexus
Diadexus was founded in 1997 and raised its 1st funding round 10 years after it was founded.
Diadexus is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Diadexus is a funded company, having raised a total of $49.2M across 3 funding rounds to date.
Diadexus develops molecular diagnostic tests for cardiovascular disorders. It currently has two products on the market (under the PLAC trademark) that test Lipoprotein-associated phospholipase A2 (Lp-PLA2) levels. the PLAC Test ELISA kit that assesses the risk of coronary heart disease and ischemic stroke associated with atherosclerosis, while the PLAC Test for Lp-PLA2 Activity that evaluates the risk of coronary heart disease in patients with no prior history of cardiovascular disease. In addition, the company has other biomarker-based tests for heart failure in the pipeline. The lead heart failure biomarker proADM (mid-regional pro-adrenomedullin) has entered formal development on the ELISA platform for a planned 510(k) regulatory submission to the FDA in early 2016. In 2014, Diadexus and Vaxgen entered into a reverse merger agreement, and the combined company was renamed Diadexus.
Diadexus's top competitors include GEN inCode, SD Biosensor and SpectraWAVE.
Diadexus offers Serum Amyloid A Assay, Pancreatic Elastase Assay, DZ-Lite c270 Analyzer, OxPL Lipoprotein Assay, and Procalcitonin Assay.
Diadexus has 6 investors. Key investors include Burrill and Company, Diazyme Laboratories, Scale Venture Partners, Brookside Capital, and Mosaix Ventures.